HUP0300499A2 - Pharmaceutical formulations for dry powder inhalers - Google Patents
Pharmaceutical formulations for dry powder inhalersInfo
- Publication number
- HUP0300499A2 HUP0300499A2 HU0300499A HUP0300499A HUP0300499A2 HU P0300499 A2 HUP0300499 A2 HU P0300499A2 HU 0300499 A HU0300499 A HU 0300499A HU P0300499 A HUP0300499 A HU P0300499A HU P0300499 A2 HUP0300499 A2 HU P0300499A2
- Authority
- HU
- Hungary
- Prior art keywords
- particle size
- dry powder
- mixture
- weight
- material particles
- Prior art date
Links
- 239000000843 powder Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 239000011362 coarse particle Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
A találmány tárgya por száraz por inhalátorban való alkalmazásra, apor i) fiziológiailag elfogadható segédanyag és adalékanyagkeverékének finom részecskeméretű frakcióját, amely keverék közepesrészecskemérete 35 mm -nél kisebb; ii) fiziológiailag elfogadhatóhordozó durva részecskeméretű frakcióját, amelynek a részecskeméretelegalább 90 mm; és iii) legalább egy hatóanyagot tartalmaz; az i)keverék legalább 99 tömeg% segédanyag-részecskét és legalább 1 tömeg%adalékanyagot tartalmaz, és a finom segédanyag-részecskék és a durvahordozóanyag-részecskék aránya 1:99 és 40:60 tömeg% közötti. Atalálmány belégzés útján, száraz por formájában adagolandókészítményekre vonatkozik, amelyek alkalmasak a hatóanyagoknak apulmonális betegségektől, így például asztmától szenvedő betegek alsólégzőtraktusába való hatékony eljuttatására. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0009469.8A GB0009469D0 (en) | 2000-04-17 | 2000-04-17 | Improvements in or relating to formalities for use in inhaler devices |
EP00113608 | 2000-06-27 | ||
PCT/GB2001/001751 WO2001078695A2 (en) | 2000-04-17 | 2001-04-17 | Pharmaceutical formulations for dry powder inhalers |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300499A2 true HUP0300499A2 (en) | 2003-07-28 |
HU229270B1 HU229270B1 (en) | 2013-10-28 |
Family
ID=26071084
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300593A HU229797B1 (en) | 2000-04-17 | 2001-04-17 | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
HU0300490A HUP0300490A2 (en) | 2000-04-17 | 2001-04-17 | Formulations for use in inhaler devices |
HU0300499A HU229270B1 (en) | 2000-04-17 | 2001-04-17 | Pharmaceutical formulations for dry powder inhalers |
HU1300117A HU230464B1 (hu) | 2000-04-17 | 2001-04-17 | Kemény pelletként kialakított gyógyászati készítmény száraz porral működő inhalátorhoz |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300593A HU229797B1 (en) | 2000-04-17 | 2001-04-17 | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
HU0300490A HUP0300490A2 (en) | 2000-04-17 | 2001-04-17 | Formulations for use in inhaler devices |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU1300117A HU230464B1 (hu) | 2000-04-17 | 2001-04-17 | Kemény pelletként kialakított gyógyászati készítmény száraz porral működő inhalátorhoz |
Country Status (32)
Country | Link |
---|---|
US (4) | US8182791B2 (hu) |
EP (6) | EP1719505B1 (hu) |
JP (2) | JP2003530425A (hu) |
KR (1) | KR20030069047A (hu) |
CN (1) | CN1424909A (hu) |
AT (5) | ATE521340T1 (hu) |
AU (3) | AU784719B2 (hu) |
BR (3) | BR0110301A (hu) |
CA (3) | CA2405767C (hu) |
CY (1) | CY1107315T1 (hu) |
CZ (1) | CZ301904B6 (hu) |
DE (3) | DE60123031T2 (hu) |
DK (3) | DK1276472T3 (hu) |
DZ (1) | DZ3315A1 (hu) |
EE (1) | EE05257B1 (hu) |
ES (3) | ES2272473T3 (hu) |
GB (2) | GB2363988A (hu) |
HU (4) | HU229797B1 (hu) |
IL (1) | IL152306A0 (hu) |
MA (1) | MA26892A1 (hu) |
MX (3) | MXPA02010213A (hu) |
MY (1) | MY129384A (hu) |
NO (4) | NO342999B1 (hu) |
NZ (1) | NZ521887A (hu) |
PE (1) | PE20011227A1 (hu) |
PL (3) | PL358640A1 (hu) |
PT (3) | PT1719505E (hu) |
SA (1) | SA01220062B1 (hu) |
SI (2) | SI1274406T1 (hu) |
SK (1) | SK284248B6 (hu) |
TN (1) | TNSN01060A1 (hu) |
WO (3) | WO2001078693A2 (hu) |
Families Citing this family (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
WO2000053157A1 (en) * | 1999-03-05 | 2000-09-14 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
ATE378039T1 (de) * | 2000-06-27 | 2007-11-15 | Vectura Ltd | Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung |
GB0027357D0 (en) * | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US8580306B2 (en) * | 2000-11-30 | 2013-11-12 | Vectura Limited | Particles for use in a pharmaceutical composition |
AU2211502A (en) † | 2000-11-30 | 2002-06-11 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
ES2708961T3 (es) | 2000-11-30 | 2019-04-12 | Vectura Ltd | Composiciones farmacéuticas para inhalación |
WO2002056948A1 (en) | 2001-01-17 | 2002-07-25 | Vectura Limited | An inhaler device |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
EP1487417A4 (en) | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | DRY POWDER DRUG FORMULATIONS |
US7931533B2 (en) | 2001-09-28 | 2011-04-26 | Igt | Game development architecture that decouples the game logic from the graphics logics |
SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
EP1498116A1 (en) * | 2002-03-20 | 2005-01-19 | Hosokawa Micron Corporation | Method of manufacturing chemical-containing composite particles |
FI116657B (fi) * | 2002-03-28 | 2006-01-31 | Focus Inhalation Oy | Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö |
US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
NZ538965A (en) * | 2002-08-21 | 2006-11-30 | Norton Healthcare Ltd | Dry powder inhalation compositions |
WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
CA2522158C (en) * | 2003-04-14 | 2018-03-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US7094545B2 (en) * | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
EP1643973A1 (en) * | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Pharmaceutical formulations comprising magnesium stearate |
JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
CN1826099B (zh) * | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
ES2243840T3 (es) | 2003-07-25 | 2005-12-01 | Ferring B.V. | Composicion farmaceutica de desmopresina como forma farmaceutica solida de dosificacion y metodo para la fabricacion de la misma. |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
EP1663164A2 (en) * | 2003-09-15 | 2006-06-07 | Vectura Limited | Methods for preparing pharmaceutical compositions |
GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
WO2005053647A1 (en) * | 2003-12-03 | 2005-06-16 | Microdrug Ag | Medical product containing tiotropium |
SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
HUE042304T2 (hu) * | 2004-04-23 | 2019-06-28 | Cydex Pharmaceuticals Inc | DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
WO2006086270A1 (en) | 2005-02-10 | 2006-08-17 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
BRPI0608844A2 (pt) * | 2005-03-09 | 2010-02-02 | Ono Pharmaceutical Co | partìcula e preparação que contém a partìcula |
US20090298802A1 (en) * | 2005-03-30 | 2009-12-03 | Sequeira Joel A | Pharmaceutical Compositions |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
GB0622818D0 (en) * | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
CN101677954A (zh) | 2007-02-11 | 2010-03-24 | Map药物公司 | 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法 |
CA2693377A1 (en) | 2007-07-21 | 2009-01-29 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles |
AU2008326309C1 (en) | 2007-11-21 | 2015-03-12 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
CA2711865A1 (en) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency |
MX2010007430A (es) | 2008-01-11 | 2010-12-21 | Albany Molecular Res Inc | Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana. |
EP2080508A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
EP2191821A1 (en) | 2008-11-26 | 2010-06-02 | CHIESI FARMACEUTICI S.p.A. | Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation |
KR101675174B1 (ko) | 2009-01-26 | 2016-11-10 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 이환형 헤테로사이클릭 스피로 화합물 |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
PL2400950T3 (pl) | 2009-02-26 | 2019-12-31 | Glaxo Group Limited | Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol |
US20120101077A1 (en) * | 2009-04-24 | 2012-04-26 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
EP2360147A1 (en) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
ES2675575T3 (es) | 2010-04-01 | 2018-07-11 | Chiesi Farmaceutici S.P.A. | Proceso para preparar partículas vehículo para polvos secos para inhalación |
WO2011131663A1 (en) | 2010-04-21 | 2011-10-27 | Chiesi Farmaceutici S.P.A. | "process for providing particles with reduced electrostatic charges" |
NZ603226A (en) | 2010-04-30 | 2015-02-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
EP2575786B1 (en) | 2010-06-03 | 2017-11-15 | Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. | Process for dry powder formulations |
BR112012032330A2 (pt) | 2010-06-22 | 2016-11-08 | Chiesi Farma Spa | formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem |
PE20130601A1 (es) * | 2010-08-03 | 2013-05-30 | Chiesi Farma Spa | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa |
EP2611416B1 (en) * | 2010-09-03 | 2015-08-19 | Pharmaterials Ltd. | Pharmaceutical composition suitable for use in a dry powder inhaler |
EP2621484A1 (en) | 2010-09-29 | 2013-08-07 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
KR20140005150A (ko) | 2010-09-30 | 2014-01-14 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도 |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
EP2804583A1 (en) * | 2012-01-16 | 2014-11-26 | Mahmut Bilgic | Dry powder formulations comprising r-formoterol as active agent |
WO2013109215A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Preparation of dry powder formulations comprising formoterol |
WO2013109210A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Dry powder formulations comprising budesonide |
PT3527197T (pt) | 2012-01-25 | 2022-10-26 | Chiesi Farm Spa | Formulação de um pó seco compreendendo um corticosteroide e um adrenérgico beta para administração por inalação |
WO2013114374A1 (en) | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
US20150136130A1 (en) | 2012-02-29 | 2015-05-21 | Pulmatrix, Inc. | Inhalable dry powders |
EP2834244B1 (en) | 2012-03-13 | 2016-08-10 | Respivert Limited | Crystalline pi3 kinase inhibitors |
WO2013153146A1 (en) | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
WO2014007772A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
CA2889446C (en) | 2012-10-25 | 2021-05-11 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US11052202B2 (en) | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
CA2897464C (en) | 2013-01-28 | 2021-05-18 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
EP2991634A1 (en) | 2013-04-30 | 2016-03-09 | Otitopic Inc. | Dry powder formulations and methods of use |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
TR201802969T4 (tr) * | 2013-07-01 | 2018-03-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Yeni inhalasyon formülasyonları. |
EA029125B1 (ru) * | 2013-07-11 | 2018-02-28 | Кьези Фармасьютичи С.П.А. | Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции |
US20160235667A1 (en) * | 2013-10-02 | 2016-08-18 | Vectura Limited | Method and apparatus for making compositions for pulmonary administration |
US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
EP3060205A4 (en) | 2013-10-22 | 2017-06-28 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
EP2957552B1 (en) | 2014-06-16 | 2020-01-22 | Arven Ilac Sanayi Ve Ticaret A.S. | Vilanterol formulations |
TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
US20180021256A1 (en) * | 2014-07-09 | 2018-01-25 | Arven Ilac Sanayi Ve Ticaret A.S. | Process for the preparation of formulations for inhalation |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
CN107106641B (zh) | 2014-10-31 | 2021-12-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 粉末制剂 |
WO2016209208A1 (en) * | 2015-06-23 | 2016-12-29 | Schlumberger Canada Limited | Mobile proppant recognition |
US11224594B2 (en) * | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
EA037716B1 (ru) | 2015-11-16 | 2021-05-13 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство, порошковая композиция, ингалятор, применение сухой порошковой композиции для профилактики и/или лечения воспалительного и/или обструктивного заболевания дыхательных путей |
SG10201912090UA (en) * | 2015-11-16 | 2020-02-27 | Chiesi Farm Spa | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
JP7242300B2 (ja) | 2015-12-24 | 2023-03-20 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | ニコチン粒子カプセル |
WO2018045217A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
BR112019023378A2 (pt) * | 2017-05-11 | 2020-06-16 | Chiesi Farmaceutici S.P.A. | Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco |
MX2019012930A (es) * | 2017-05-11 | 2020-01-14 | Chiesi Farm Spa | Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico. |
US10583085B2 (en) | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
BR112020000766A2 (pt) | 2017-07-14 | 2020-07-21 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 e seus usos |
WO2019019040A1 (en) * | 2017-07-26 | 2019-01-31 | Shenzhen Xpectvision Technology Co., Ltd. | SYSTEM HAVING SPATIALLY EXPANDED X-RAY SOURCE FOR X-RAY IMAGING |
SI3658184T1 (sl) | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
WO2019060604A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
WO2019060797A1 (en) | 2017-09-22 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | PROCESS FOR PRODUCING POWDERS FOR INHALING |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
WO2019067708A1 (en) * | 2017-09-27 | 2019-04-04 | Teva Branded Pharmaceutical Products R&D, Inc. | METHOD FOR DECREASING PARTICLE SIZE |
EP3817739A4 (en) * | 2018-07-02 | 2022-04-13 | The General Hospital Corporation | SODIUM CROMOGLYCATE AND ?-LACTOSE POWDER FORMULATIONS |
CN112469443B (zh) | 2018-07-27 | 2024-04-16 | 奇斯药制品公司 | 用于吸入用干粉制剂的新型载体颗粒 |
WO2020049505A1 (en) | 2018-09-06 | 2020-03-12 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
MA54045A (fr) | 2018-10-30 | 2021-09-08 | Chiesi Farm Spa | Appareil pour administrer des médicaments à des patients ventilés mécaniquement |
AU2019397033B2 (en) | 2018-12-12 | 2023-06-29 | Kite Pharma, Inc. | Chimeric antigen receptors and CAR-T cells and methods of use |
EP3962472A4 (en) | 2019-04-29 | 2023-01-25 | Insmed Incorporated | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF |
EP4034079A1 (en) | 2019-09-24 | 2022-08-03 | Chiesi Farmaceutici S.p.A. | Novel carrier particles for dry powder formulations for inhalation |
EP4138911A1 (en) | 2020-04-24 | 2023-03-01 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
US20230277524A1 (en) | 2020-05-22 | 2023-09-07 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
CN112451509B (zh) * | 2020-12-19 | 2023-03-07 | 沈阳药科大学 | 一种川丁特罗吸入粉雾剂及其制备方法 |
WO2022215054A1 (en) | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
US20230018888A1 (en) | 2021-04-26 | 2023-01-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
AU2022266584A1 (en) | 2021-04-26 | 2023-10-12 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
AU2022372894A1 (en) | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
GB1381872A (en) | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
GB1520247A (en) | 1974-08-10 | 1978-08-02 | Fisons Ltd | Pelletised medicament formulations |
GB1571629A (en) | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
US4349542A (en) * | 1979-06-08 | 1982-09-14 | National Research Development Corporation | Mixture containing active ingredient and dendritic crystalline sugar for tableting |
IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
ATE94801T1 (de) | 1990-01-29 | 1993-10-15 | Ciba Geigy Ag | Verfahren und vorrichtung zur dosierung eines feinkoernigen pulvers. |
DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
AU660824B2 (en) | 1992-06-12 | 1995-07-06 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
SE9700136D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
CA2305260A1 (en) * | 1997-09-30 | 1999-04-08 | Mortimer Technology Holdings Limited | A process and apparatus for treating particulate matter |
EA003196B1 (ru) * | 1998-03-16 | 2003-02-27 | Инхэл Терапьютик Системз, Инк | Способ подачи действующего вещества в виде аэрозоля |
ES2192866T3 (es) | 1998-11-13 | 2003-10-16 | Jago Res Ag | Polvo seco para inhalacion. |
GB9826783D0 (en) * | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
WO2000053157A1 (en) | 1999-03-05 | 2000-09-14 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
ATE313318T1 (de) * | 1999-10-29 | 2006-01-15 | Nektar Therapeutics | Trockenpulverzusammensetzungen mit verbesserter dispersität |
GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
ATE378039T1 (de) * | 2000-06-27 | 2007-11-15 | Vectura Ltd | Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung |
-
2001
- 2001-04-11 PE PE2001000338A patent/PE20011227A1/es active IP Right Grant
- 2001-04-16 TN TNTNSN01060A patent/TNSN01060A1/fr unknown
- 2001-04-17 EP EP06017742A patent/EP1719505B1/en not_active Expired - Lifetime
- 2001-04-17 PT PT06017742T patent/PT1719505E/pt unknown
- 2001-04-17 MX MXPA02010213A patent/MXPA02010213A/es active IP Right Grant
- 2001-04-17 WO PCT/EP2001/004338 patent/WO2001078693A2/en active IP Right Grant
- 2001-04-17 CA CA2405767A patent/CA2405767C/en not_active Expired - Lifetime
- 2001-04-17 PL PL01358640A patent/PL358640A1/xx not_active Application Discontinuation
- 2001-04-17 AT AT06017742T patent/ATE521340T1/de active
- 2001-04-17 AU AU48581/01A patent/AU784719B2/en not_active Ceased
- 2001-04-17 SA SA01220062A patent/SA01220062B1/ar unknown
- 2001-04-17 MX MXPA02010212A patent/MXPA02010212A/es active IP Right Grant
- 2001-04-17 CA CA002406119A patent/CA2406119C/en not_active Expired - Lifetime
- 2001-04-17 WO PCT/GB2001/001751 patent/WO2001078695A2/en active IP Right Grant
- 2001-04-17 JP JP2001575995A patent/JP2003530425A/ja active Pending
- 2001-04-17 WO PCT/GB2001/001732 patent/WO2001078694A2/en active IP Right Grant
- 2001-04-17 MY MYPI20011834A patent/MY129384A/en unknown
- 2001-04-17 DE DE60123031T patent/DE60123031T2/de not_active Expired - Lifetime
- 2001-04-17 BR BR0110301-6A patent/BR0110301A/pt not_active Application Discontinuation
- 2001-04-17 ES ES01931612T patent/ES2272473T3/es not_active Expired - Lifetime
- 2001-04-17 IL IL15230601A patent/IL152306A0/xx unknown
- 2001-04-17 GB GB0109432A patent/GB2363988A/en not_active Withdrawn
- 2001-04-17 US US10/257,790 patent/US8182791B2/en not_active Expired - Fee Related
- 2001-04-17 AT AT01921625T patent/ATE377416T1/de not_active IP Right Cessation
- 2001-04-17 KR KR1020027013929A patent/KR20030069047A/ko not_active Application Discontinuation
- 2001-04-17 PT PT01921610T patent/PT1276472E/pt unknown
- 2001-04-17 HU HU0300593A patent/HU229797B1/hu unknown
- 2001-04-17 EP EP07110708A patent/EP1829533B1/en not_active Revoked
- 2001-04-17 US US10/257,368 patent/US6884794B2/en not_active Expired - Lifetime
- 2001-04-17 EE EEP200200593A patent/EE05257B1/xx unknown
- 2001-04-17 HU HU0300490A patent/HUP0300490A2/hu unknown
- 2001-04-17 HU HU0300499A patent/HU229270B1/hu unknown
- 2001-04-17 CA CA2406201A patent/CA2406201C/en not_active Expired - Fee Related
- 2001-04-17 AT AT07110708T patent/ATE513542T1/de active
- 2001-04-17 AT AT01931612T patent/ATE339195T1/de active
- 2001-04-17 DK DK01921610T patent/DK1276472T3/da active
- 2001-04-17 GB GB0109431A patent/GB2363987A/en not_active Withdrawn
- 2001-04-17 BR BR0110141-2A patent/BR0110141A/pt not_active Application Discontinuation
- 2001-04-17 CZ CZ20023437A patent/CZ301904B6/cs not_active IP Right Cessation
- 2001-04-17 SI SI200130658T patent/SI1274406T1/sl unknown
- 2001-04-17 EP EP10185445.3A patent/EP2272508B1/en not_active Expired - Lifetime
- 2001-04-17 HU HU1300117A patent/HU230464B1/hu unknown
- 2001-04-17 AU AU48595/01A patent/AU4859501A/en not_active Abandoned
- 2001-04-17 EP EP01921610A patent/EP1276472B1/en not_active Revoked
- 2001-04-17 SK SK1491-2002A patent/SK284248B6/sk not_active IP Right Cessation
- 2001-04-17 ES ES01921610T patent/ES2275669T3/es not_active Expired - Lifetime
- 2001-04-17 PT PT01931612T patent/PT1274406E/pt unknown
- 2001-04-17 DE DE60125344T patent/DE60125344T2/de not_active Expired - Lifetime
- 2001-04-17 MX MXPA02010218A patent/MXPA02010218A/es active IP Right Grant
- 2001-04-17 EP EP01921625A patent/EP1276473B1/en not_active Revoked
- 2001-04-17 ES ES01921625T patent/ES2292576T3/es not_active Expired - Lifetime
- 2001-04-17 BR BR0110139-0A patent/BR0110139A/pt not_active Application Discontinuation
- 2001-04-17 DK DK01931612T patent/DK1274406T3/da active
- 2001-04-17 DZ DZ013315A patent/DZ3315A1/fr active
- 2001-04-17 PL PL359289A patent/PL204251B1/pl unknown
- 2001-04-17 NZ NZ521887A patent/NZ521887A/en unknown
- 2001-04-17 AU AU2001258343A patent/AU2001258343A1/en not_active Abandoned
- 2001-04-17 PL PL358875A patent/PL204213B1/pl unknown
- 2001-04-17 CN CN01808256A patent/CN1424909A/zh active Pending
- 2001-04-17 AT AT01921610T patent/ATE348603T1/de active
- 2001-04-17 DE DE60131265T patent/DE60131265T2/de not_active Revoked
- 2001-04-17 EP EP01931612A patent/EP1274406B1/en not_active Expired - Lifetime
- 2001-04-17 DK DK06017742.5T patent/DK1719505T3/da active
- 2001-04-17 SI SI200131003T patent/SI1719505T1/sl unknown
-
2002
- 2002-10-04 MA MA26851A patent/MA26892A1/fr unknown
- 2002-10-16 NO NO20024973A patent/NO342999B1/no not_active IP Right Cessation
- 2002-10-16 NO NO20024980A patent/NO332025B1/no not_active IP Right Cessation
- 2002-10-16 NO NO20024971A patent/NO20024971L/no not_active Application Discontinuation
-
2005
- 2005-03-08 US US11/073,625 patent/US7223748B2/en not_active Expired - Lifetime
-
2006
- 2006-11-28 CY CY20061101708T patent/CY1107315T1/el unknown
-
2011
- 2011-06-20 NO NO20110885A patent/NO336687B1/no not_active IP Right Cessation
-
2012
- 2012-04-25 US US13/455,277 patent/US20120308613A1/en not_active Abandoned
- 2012-09-28 JP JP2012217416A patent/JP2012255035A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300499A2 (en) | Pharmaceutical formulations for dry powder inhalers | |
JO3102B1 (ar) | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة | |
RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
JO2430B1 (en) | Pharmaceutical formulas for dry powder inhalations in the form of solid pellets | |
MX2022001724A (es) | Composicion farmaceutica que comprende ensifentrina. | |
HUP0002533A2 (hu) | Asztmaellenes gyógyszerhatóanyagok új kombinációja | |
PL365736A1 (en) | Bimodal dry powder formulation for inhalation | |
JP2002161030A (ja) | 異なる粒径をもった混合粉体の吸入方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: VECTURA LIMITED, GB Free format text: FORMER OWNER(S): VECTURA LIMITED, GB; VECTURA GROUP PLC, GB; VECTURA LIMITED, GB |
|
HC9A | Change of name, address |
Owner name: VECTURA LIMITED, GB Free format text: FORMER OWNER(S): VECTURA LIMITED, GB; VECTURA GROUP PLC, GB; VECTURA LIMITED, GB |